Retention of the radiotracers 64Cu-ATSM and 64Cu-PTSM in human and murine tumors is influenced by MDR1 protein expression

Journal of Nuclear Medicine

Volumn 50, Issue 8, 2009, Pages 1332-1339

  Liu, Jun ^a,b   Hajibeigi, Asghar ^a   Ren, Gang ^a   Lin, Mai ^a   Siyambalapitiyage, Wasana ^a   Liu, Zhisu ^b   Simpson, Evan ^c   Parkey, Robert W ^a   Sun, Xiankai ^a   Öz, Orhan K ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

^c HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Copper diacetyl bis(N4 methylthiosemicarbazone); Copper pyruvaldehyde bis(N4 methylthiosemicarbazone); Hypoxia imaging; MDR1; P glycoprotein (Pgp)

Indexed keywords

AROMATASE; COPPER 64; DIACETYLBIS(N4 METHYLTHIOSEMICARBAZONE) COPPER CU 64; MULTIDRUG RESISTANCE PROTEIN 1; PYRUVALDEHYDE BIS(N4 METHYLTHIOSEMICARBAZONE) COPPER CU 64; THIOSEMICARBAZONE DERIVATIVE; UNCLASSIFIED DRUG; ABCB1 PROTEIN, HUMAN; COPPER (II) DIACETYL DI(N(4) METHYLTHIOSEMICARBAZONE); COPPER (II) DIACETYL-DI(N(4)-METHYLTHIOSEMICARBAZONE); COPPER PYRUVALDEHYDE BIS(N(4) METHYLTHIOSEMICARBAZONE) COMPLEX; COPPER PYRUVALDEHYDE BIS(N(4)-METHYLTHIOSEMICARBAZONE) COMPLEX; DIAGNOSTIC AGENT; GLYCOPROTEIN P; ORGANOMETALLIC COMPOUND; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER DIAGNOSIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG PROTEIN BINDING; DRUG RETENTION; HUMAN; HUMAN CELL; IN VIVO STUDY; KNOCKOUT MOUSE; LIVER TUMOR; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT; WILD TYPE; ANIMAL; COMPARATIVE STUDY; EVALUATION; GENE EXPRESSION REGULATION; METABOLIC CLEARANCE RATE; METABOLISM; SCINTISCANNING; TISSUE DISTRIBUTION;

ANIMALS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MALE; METABOLIC CLEARANCE RATE; MICE; ORGANOMETALLIC COMPOUNDS; P-GLYCOPROTEIN; RADIOPHARMACEUTICALS; THIOSEMICARBAZONES; TISSUE DISTRIBUTION;

EID: 68249133609     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.109.061879     Document Type: Article

References (39)

1. Brown JM. The hypoxic cell: a target for selective cancer therapy - eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res. 1999;59:5863-5870.
2. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002;2:48-58.
3. Endicott JA, Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem. 1989;58:137-171.
4. Piwnica-Worms D, Chiu ML, Budding M, Kronauge JF, Kramer RA, Croop JM. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res. 1993;53:977-984.
5. Aratani T, Narabayashi I, Komori T, et al. Usefulness of Tc-99m MIBI SPECT in predicting multidrug resistance gene expression levels in non-small cell lung cancer: a preliminary report. Ann Nucl Med. 2001;15:313-319.
6. 99mTc-MIBI imaging as a predictor of therapy response in osteosarcoma compared with multidrug resistance-associated protein and P-glycoprotein expression. J Nucl Med. 2003;44:1394-1401.
7. Cermik TF, Altiay G, Firat MF, Hatipoglu ON, Berkarda S. Assessment of Tc-99m sestamibi tumor tissue uptake under the influence of increased arterial oxygen saturation. Nucl Med Biol. 2005;32:165-170.
8. 99mTc-tetrofosmin uptake in MRP-expressing breast cancer cells under hypoxic conditions is independent of MRP function. Eur J Nucl Med Mol Imaging. 2003; 30:1529-1531.
9. 99mTc-HL91. Eur J Nucl Med Mol Imaging. 2002;29:1006-1011.
10. 99mTc-MIBI imaging in patients with lung cancer. J Nucl Med. 2001;42:1476-1483.
11. 18F-fluoromisonidazole. Semin Nucl Med. 2007;37:451-461.
12. Vavere AL, Lewis JS. Cu-ATSM: a radiopharmaceutical for the PET imaging of hypoxia. Dalton Trans. 2007;43:4893-4902.
13. Petering HG, Buskirk HH, Underwood GE. The anti-tumor activity of 2-keto-3-ethoxybutyraldehyde bis(thiosemicarbazone) and related compounds. Cancer Res. 1964;24:367-372.
14. Fujibayashi Y, Taniuchi H, Yonekura Y, Ohtani H, Konishi J, Yokoyama A. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med. 1997;38:1155-1160.
15. 60Cu-ATSM: relationship to therapeutic response - a preliminary report. Int J Radiat Oncol Biol Phys. 2003;55:1233-1238.
16. 60Cu-ATSM. Eur J Nucl Med Mol Imaging. 2003;30:844-850.
17. 18F]fluoromisonidazole positron emission tomography. Int J Oncol. 2007; 30:873-881.
18. 2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. Int J Radiat Oncol Biol Phys. 2005;61:1493-1502.
19. 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone). J Nucl Med. 2006;47:989-998.
20. Harker WG, Sikic BI. Multidrug (pleiotropic) resistance in doxorubicin-selected variants of the human sarcoma cell line MES-SA. Cancer Res. 1985;45:4091-4096.
21. Fisher CR, Graves KH, Parlow AF, Simpson ER. Characterization of mice deficient in aromatase (ArKO) because of targeted disruption of the cyp19 gene. Proc Natl Acad Sci USA. 1998;95:6965-6970.
22. Fujibayashi Y, Yoshimi E, Waki A, et al. A novel 111In-labeled antisense DNA probe with multi-chelating sites (MCS-probe) showing high specific radioactivity and labeling efficiency. Nucl Med Biol. 1999;26:17-21.
23. Young H, Carnochan P, Zweit J, Babich J, Cherry S, Ott R. Evaluation of copper(II)-pyruvaldehyde bis (N-4-methylthiosemicarbazone) for tissue blood flow measurement using a trapped tracer model. Eur J Nucl Med. 1994;21:336-341.
24. Hirasawa G, Simpson ER, Oz OK. Increased incidence of hepatic masses in aromatase deficient mice. Paper presented at: ENDO 2002, The Endocrine Society's 84th Annual Meeting; 2002; San Francisco, CA.
25. Rice GC, Ling V, Schimke RT. Frequencies of independent and simultaneous selection of Chinese hamster cells for methotrexate and doxorubicin (adriamycin) resistance. Proc Natl Acad Sci USA. 1987;84:9261-9264.
26. Liang BC. Effects of hypoxia on drug resistance phenotype and genotype in human glioma cell lines. J Neurooncol. 1996;29:149-155.
27. Luk CK, Veinot-Drebot L, Tjan E, Tannock IF. Effect of transient hypoxia on sensitivity to doxorubicin in human and murine cell lines. J Natl Cancer Inst. 1990;82:684-692.
28. Sakata K, Kwok TT, Murphy BJ, Laderoute KR, Gordon GR, Sutherland RM. Hypoxia-induced drug resistance: comparison to P-glycoprotein-associated drug resistance. Br J Cancer. 1991;64:809-814.
29. Jones ME, Thorburn AW, Britt KL, et al. Aromatase-deficient (ArKO) mice have a phenotype of increased adiposity. Proc Natl Acad Sci USA. 2000;97:12735-12740.
30. Ciarmiello A, Del Vecchio S, Silvestro P, et al. Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol. 1998;16:1677-1683.
31. Kunishio K, Okada M, Matsumoto Y, Nagao S, Nishiyama Y. Technetium-99m sestamibi single photon emission computed tomography findings correlated with P-glycoprotein expression in pituitary adenoma. J Med Invest. 2006;53:285-291.
32. Shih CM, Hsu WH, Huang WT, Wang JJ, Ho ST, Kao A. Usefulness of chest single photon emission computed tomography with technetium-99m methoxyisobutylisonitrile to predict taxol based chemotherapy response in advanced non-small cell lung cancer. Cancer Lett. 2003;199:99-105.
33. Vecchio SD, Ciarmiello A, Potena MI, et al. In vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients. Eur J Nucl Med. 1997;24:150-159.
34. Obata A, Yoshimi E, Waki A, et al. Retention mechanism of hypoxia selective nuclear imaging/radiotherapeutic agent cu-diacetyl-bis(N4- methylthiosemicarbazone) (Cu-ATSM) in tumor cells. Ann Nucl Med. 2001;15:499-504.
35. Dearling JL, Lewis JS, Mullen GE, Welch MJ, Blower PJ. Copper bis(thiosemicarbazone) complexes as hypoxia imaging agents: structure-activity relationships. J Biol Inorg Chem. 2002;7:249-259.
36. Maurer RI, Blower PJ, Dilworth JR, Reynolds CA, Zheng Y, Mullen GE. Studies on the mechanism of hypoxic selectivity in copper bis(thiosemicarbazone) radiopharmaceuticals. J Med Chem. 2002;45:1420-1431.
37. Burgman P, O'Donoghue JA, Lewis JS, Welch MJ, Humm JL, Ling CC. Cell line-dependent differences in uptake and retention of the hypoxia-selective nuclear imaging agent Cu-ATSM. Nucl Med Biol. 2005;32:623-630.
38. Lewis J, Laforest R, Buettner T, et al. Copper-64-diacetyl-bis(N4- methylthiosemicarbazone): an agent for radiotherapy. Proc Natl Acad Sci USA. 2001;98:1206-1211.
39. Aft RL, Lewis JS, Zhang F, Kim J, Welch MJ. Enhancing targeted radiotherapy by copper(II)diacetyl-bis(N4-methylthiosemicarbazone) using 2-deoxy-D-glucose. Cancer Res. 2003;63:5496-5504.